Underwriting AgreementUnderwriting Agreement • June 10th, 2013 • Array Biopharma Inc • Pharmaceutical preparations • New York
Array BioPharma Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $115,000,000 principal amount of the 3.00% Convertible Senior Notes due 2020 (the “Firm Securities”), convertible into shares of Common Stock, par value $0.001 (“Stock”) of the Company and, at the election of the Underwriters, up to an aggregate of $17,250,000 additional principal amount of 3.00% Convertible Senior Notes due 2020 (the “Optional Securities”) (the Firm Securities and the Optional Securities which the Underwriters elect to purchase pursuant to Section 2 hereof are herein called the “Securities”).
NINTH AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 10th, 2013 • Array Biopharma Inc • Pharmaceutical preparations
This Ninth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of June 4, 2013, by and between COMERICA BANK (“Bank”) and ARRAY BIOPHARMA, INC. (“Borrower”) to be effective as of the Effective Time (as defined below).
